# Zoar Engelman

> Zoar Engelman is the co-founder and CEO of Axon Therapies, a clinical-stage medical device company chasing a stubborn problem: heart failure with preserved ejection fraction, a condition that has resisted nearly every drug thrown at it. A biomedical engineer with a PhD from the University of Auckland, Engelman spent two decades turning lab ideas into implantable and catheter-based devices, co-founding roughly nine ventures and helping raise more than $150 million along the way. In September 2025 he stepped up from Chief Scientific Officer to CEO as Axon closed an oversubscribed $32 million Series A to advance SAVM, an implant-free procedure that quiets an overactive sympathetic nervous system to rebalance the body's blood volume.

- **Role:** Co-founder & CEO at Axon Therapies Inc.
- **Organizations:** Axon Therapies Inc., Coridea, Deerfield Catalyst, Cibiem, Inc., Corvent Medical Inc., EP Sciences, LLC
- **Education:** B.S. in Biomedical Engineering, University of Utah, M.S. in Biomedical Engineering, University of Utah, Ph.D. in Bioengineering, University of Auckland
- **Known for:** Co-founded roughly nine medtech ventures since 2011, Helped raise more than $150 million in funding across his ventures, Co-founded Axon Therapies and developed the SAVM (Splanchnic Ablation for Volume Management) procedure

## Career timeline

- **2002** — Research Assistant, University of Utah
- **2002-2005** — Research Assistant, Cardiovascular Research and Training Institute
- **2006-2011** — Researcher and Doctoral Candidate, Auckland Bioengineering Institute
- **2011-2012** — Senior Biomedical Systems Engineer, Coridea NC1, Inc.
- **2012-2016** — Director of Research, Cibiem, Inc.
- **2016-2020** — Chief Science Officer, Coridea, LLC
- **2020** — Co-founded Axon Therapies; served as Chief Scientific Officer
- **2025-09** — Appointed CEO of Axon Therapies as the company closed a $32M oversubscribed Series A

## Achievements

- Co-founded roughly nine medtech ventures since 2011
- Helped raise more than $150 million in funding across his ventures
- Co-founded Axon Therapies and developed the SAVM (Splanchnic Ablation for Volume Management) procedure
- Led development of the Satera Ablation System, a catheter-based, implant-free heart failure therapy
- Promoted from Chief Scientific Officer to CEO of Axon Therapies in September 2025
- Closed an oversubscribed $32 million Series A financing round

## Latest updates

- **2025-09** — Named CEO of Axon Therapies as the company raised an oversubscribed $32M Series A led by Earlybird Venture Capital and Santé Ventures.
- **2025-09** — Axon opened a new European headquarters in Altrincham, UK to accelerate clinical trial efforts.

## Links

- Website: https://axontherapies.com
- LinkedIn: http://www.linkedin.com/in/zoar-engelman-b0687421

---

Profile page: https://yespress.io/zoar-engelman
Published by YesPress — https://yespress.io
Last updated: 2026-07-07